Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger

Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.